Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.64 |
| ▸ | CASP3 | P42574 | 1/20 | 0.64 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.64 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | FAAH | O00519 | 3/20 | 0.54 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.54 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1028676 | 0.98 | EPHX2 (0.68) | EPHX2ALDH1A1LMNAPARP10CASP3 | |
| SCHEMBL11755572 | 0.94 | PARP10 (0.71) | EPHX2ALDH1A1LMNAPARP10CASP3 | |
| SCHEMBL1977190 | 0.90 | ALDH1A1 (0.70) | EPHX2ALDH1A1LMNAPARP10CASP3 | |
| SCHEMBL22563077 | 0.89 | EPHX2 (0.63) | EPHX2ALDH1A1LMNAPARP10CASP3 | |
| SCHEMBL15131945 | 0.88 | PARP10 (0.58) | EPHX2ALDH1A1LMNAPARP10CASP3 | |
| SCHEMBL11576648 | 0.87 | PARP10 (0.66) | EPHX2ALDH1A1LMNAPARP10CASP3 | |
| Hydrochloric Acid SCHEMBL6539076 | 0.87 | EPHX2 (0.56) | EPHX2ALDH1A1LMNAPARP10CASP3 | |
| SCHEMBL13266897 | 0.85 | ALDH1A1 (0.64) | EPHX2ALDH1A1LMNAPARP10CASP3 | |
| SCHEMBL12431956 | 0.85 | MAOB (0.56) | EPHX2ALDH1A1LMNAPARP10CASP3 | |
| SCHEMBL19381882 | 0.84 | PARP10 (0.90) | EPHX2ALDH1A1LMNAPARP10SENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| CN-114085207-B | Bruton tyrosine protein kinase inhibitor and application thereof | 广州百霆医药科技有限公司 | 2024-06-25 | — | — | CN | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-20240024302-A1 | SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-01-25 | — | — | US | disclosed |
| EP-4216946-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Achillion Pharmaceuticals, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| CN-116437913-A | Pharmaceutical compounds for treating complement-mediated disorders | 艾其林医药公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2022066774-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| CN-114085207-A | Bruton tyrosine protein kinase inhibitor and application thereof | 广州百霆医药科技有限公司 | 2022-02-25 | — | — | CN | disclosed |
| US-20210179549-A1 | CO-CRYSTAL OF SORAFENIB DERIVATIVES AND PROCESS FOR PREPARATION THEREOF | EICOSIS, LLC | 2021-06-17 | — | — | US | disclosed |
| CN-108085021-B | Liquid crystal aligning agent, liquid crystal alignment film, liquid crystal display element and reaction product | JSR株式会社 | 2021-06-08 | — | — | CN | disclosed |
| CN-1240713-C | New compound | FUJISAWA PHARMACEUTICAL CO (JP) | 2006-02-08 | — | — | CN | disclosed |
| EP-0934276-B1 | ANTHRANILIC ACID DERIVATIVES AS MULTI DRUG RESISTANCE MODULATORS | XENOVA LTD (GB) | 2003-12-17 | — | — | EP | disclosed |
| CN-1296494-A | New compound | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-05-23 | — | — | CN | disclosed |
| US-6218393-B1 | IN THERAPY OF MULTIDRUG RESISTANT CANCERS, FOR EXAMPLE TO POTENTIATE CYTOTOXICITY OF CANCER DRUG | XENOVA LIMITED (GB) | 2001-04-17 | — | — | US | disclosed |
| CN-1241181-A | Pharmaceutical compounds | XENOVA LTD (GB) | 2000-01-12 | — | — | CN | disclosed |
| EP-0934276-A1 | ANTHRANILIC ACID DERIVATIVES AS MULTI DRUG RESISTANCE MODULATORS | XENOVA LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998017648-A1 | ANTHRANILIC ACID DERIVATIVES AS MULTI DRUG RESISTANCE MODULATORS | XENOVA LIMITED (GB) | 1998-04-30 | — | — | WO | disclosed |
| EP-0161939-B1 | ARYLHYDROXAMATES | E.R. Squibb & Sons, Inc. (US) | 1993-07-21 | — | — | EP | disclosed |
| US-4607053-A | L2POXYGENASE INHIBITORS | E. R. SQUIBB & SONS, INC. (US) | 1986-08-19 | — | — | US | disclosed |
| EP-0161939-A2 | Arylhydroxamates | E.R. Squibb & Sons, Inc. (US) | 1985-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | EPHX2 3595/4885ALDH1A1 3835/4885LMNA 345/4885 |
| US-20210179549-A1 | CO-CRYSTAL OF SORAFENIB DERIVATIVES AND PROCESS FOR PREPARATION THEREOF | EPHX1, VKORC1, VKORC1L1 | EPHX2 4/4885ALDH1A1 628/4885LMNA 2075/4885 |
| US-20240024302-A1 | SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY | EPHX1, EPHX2, PTGER1 | EPHX2 2/4885ALDH1A1 125/4885LMNA 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.